Abstract
Long-term stability in randomized and non-randomized patients in the phase 3 randomized, double-blind EDGE trial of once- versus twice-daily dosing of eliglustat in patients with Gaucher disease type 1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have